Taiho Pharmaceutical to acquire Araris Biotech for up to $1.14bn.

Taiho Pharmaceutical, a Japanese pharmaceutical company, agreed to acquire Araris Biotech, a Swiss biotechnology company developing next-generation antibody drug conjugates, for up to $1.14bn. "Araris’ unique ADC technology represents a quantum leap for the ADC field, potentially offering precise payload delivery of multiple mechanisms of action simultaneously to the tumor, with less toxicity. We are proud to combine with Taiho, our partner since November 2023, whose significant cancer expertise will support us in turbo-charging the clinical development of our potent ADC candidates in hematological and solid tumors," Dragan Grabulovski, Araris CEO and Co-founder.